The Triple Agonist

The arrival of GLP-1 receptor agonists changed the treatment curve. In STEP 1, semaglutide established roughly 15% mean weight loss. In SURMOUNT-1, tirzepatide pushed the benchmark past 20%. That was a massive leap for drugs, but it still left room below the highest-efficacy surgical outcomes.

Eli Lilly's development bet was straightforward: if one receptor moved the field and two receptors moved it further, a carefully tuned third receptor might raise the ceiling again.

wave 1 -- GLP-1 agonists: liraglutide and then semaglutide proved that targeting the GLP-1 receptor could suppress appetite, slow gastric emptying, and improve glucose control. semaglutide was the first obesity drug to make ~15% weight loss feel reproducible rather than exceptional.

wave 2 -- dual GIP/GLP-1 agonists: tirzepatide added GIP receptor agonism and pushed mean losses above 20% in SURMOUNT-1. that result suggested the field was not capped by GLP-1 biology alone.

wave 3 -- triple GIP/GLP-1/glucagon agonists: retatrutide layered in glucagon receptor activity. that added an energy-expenditure and hepatic fat-mobilization component on top of appetite suppression and incretin signaling, producing the 24.2% Phase 2 result that made triple agonism the new frontier.

each receptor contributes something different to weight loss:

GIP receptor: glucose-dependent insulinotropic polypeptide receptor. involved in fat metabolism, energy expenditure, and beta-cell function. this is the component shared with tirzepatide.

GLP-1 receptor: glucagon-like peptide-1 receptor. suppresses appetite via the hypothalamus, delays gastric emptying, and stimulates glucose-dependent insulin secretion. this is the component shared with semaglutide.

glucagon receptor: the key differentiator. activates thermogenesis (increased energy expenditure through heat production), mobilizes fat from the liver, and promotes lipid oxidation. historically avoided because glucagon raises blood sugar, but simultaneous GLP-1 agonism counterbalances this effect.

Jastreboff et al. randomized 338 adults with obesity (BMI >= 30, or >= 27 with comorbidities) to receive weekly subcutaneous injections of retatrutide at various doses or placebo for 48 weeks. the results were dose-dependent:

at 1 mg: about 8.7% body weight loss. at 4 mg: about 17%. at 8 mg: about 23%. at 12 mg: 24.2%. placebo landed near 2.1%. every active dose beat placebo, and the top tiers pushed into the range that clinicians previously associated mostly with surgery.

notably, the 48-week curves had not clearly plateaued at the higher doses, which is one reason the late-stage TRIUMPH program matters so much: it will test whether the Phase 2 magnitude, durability, and tolerability hold up at scale.

the public program now includes the core obesity registrational studies plus newer extensions such as TRIUMPH-5 (head-to-head against tirzepatide) and TRIUMPH-Outcomes (cardiovascular and kidney endpoints). in other words, the development story is no longer just "does retatrutide lower weight?" but also how durable, how competitive, and what happens to harder cardiometabolic outcomes.

in the units ahead, you'll move from the molecule itself to each of the three receptor pathways, then into the clinical evidence, safety profile, practical dosing, and the competitive obesity-drug landscape. each major claim is paired with its primary source.